Epilepsy Medical Cannabis Studies

• View All (505)

Activation of the Cannabinoid Type-1 Receptor Mediates the Anticonvulsant Properties of Cannabinoids in the Hippocampal Neuronal Culture Models of Acquired Epilepsy and Status Epilepticus (2006)

Cannabinoids have anticonvulsant properties, but their effects have not been evaluated in hippocampal neuronal culture models of acquired epilepsy (AD) and status epilepticus (SE). The results of this study represent powerful tools to investigate the molecular mechanisms that mediate the effects of cannabinoids on neuronal excitability. View study
Analysis of endocannabinoid signaling elements and related proteins in lymphocytes of patients with Dravet syndrome (2016)

This study demonstrates that CBD or cannabidiol helps reduce seizures of childhood epilepsy, and dravets syndrome. View study
Assessment of the role of CB receptors in cannabinoid 1 anticonvulsant effects (2001)

It has been shown that cannabinoids are anticonvulsants in the maximum electroshock. This study establishes a role for the CB1 receptor in modulating convulsive activity in an animal model. View study
Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome. (2019)

Epilepsy is one of the most common chronic brain disorders that affects around 70 million people worldwide. The objective of this article was to make a critical review of the pharmacology of Cannabidiol (CBD) and the most recent clinical studies who evaluated its efficacy and safety as a complementary treatment for seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS). View study
Cannabidiol did not induce teratogenicity or neurotoxicity in exposed zebrafish embryos. (2018)

The toxicity studies of Cannabidiol (CBD) are of great importance to ensure the safety of patients. In this context, the morphological analysis of the zebrafish can contribute to evaluate the teratogenic potential, as well as the evaluation of the acetylcholinesterase activity and the motor activity of the zebrafish are valuable tools to verify the potential of neurotoxicity. The results suggest that the effects observed after exposure to CBD are closely related to the CB1 receptor that is present in the zebrafish from the earliest stages of development. View study
Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo (2009)

It is demonstrated that phytocannabinoids have important therapeutic properties, and specifically cannabidiol or CBD has anticonvulsant properties in animal models which highlights its potential as a new antiepileptic drug. View study
Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures (2012)

In this study, cannabidiol is evidenced as a strong candidate to treat human epilepsies, since it reduces the severity of seizures. View study
Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial (2018)

The Lennox-Gastaut syndrome is a severe form of epileptic encephalopathy resistant to conventional treatments. It has been shown that cannabidiol is effective for the treatment of patients with gout attacks associated with Lennox-Gastaut syndrome and is generally well tolerated. View study
Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders (2014)

It has been shown that pure cannabidiol (CBD) has anti-inflammatory and neuroprotective properties. However, studies about the effects of CBD on epilepsy have not been conclusive. For this reason, deeper controlled studies are being planned in target intractable epilepsy populations (in patients with the Dravet and Lennox Gastaut syndromes). View study
Cannabidivarin is anticonvulsant in mouse and rat (2012)

The anticonvulsant profile of cannabidivarin CBDV is investigated for the first time in invitro and in vivo models, demonstrating that it is an effective anticonvulsant without significantly affecting normal motor function. View study
Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism (2013)

Botanical substances (BDS) derived from cannabis, rich in cannabidivarin (CBDV) and cannabidiol (CBD), showed anticonvulsant properties in three crisis models that were not mediated by the CB1 cannabinoid receptor. These findings support the clinical development of CBDV BDS for the treatment of epilepsy. View study
Cannabinoids for pediatric epilepsy? Up in smoke or real science? (2015)

Trials and controlled studies on the effects of cannabidiol in children with epilepsy have shown high quality medical evidence regarding its therapeutic benefits. View study